Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- globe salvage
研究概览
简要总结
Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute.
The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 5 Months 至 7 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients diagnosed with unilateral/bilateral retinoblastoma
排除标准
- •patients with trilateral retinoblastoma
- •extraoculer involvement
- •patients with blood dyscrasias, bleeding and clotting disorders
研究组 & 干预措施
group 1
Patients who received intra-arterial chemotherapy as a first line treatment
干预措施: intra-arterial administration of melphalan (Drug)
group 2
Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
干预措施: intra-arterial administration of melphalan (Drug)
结局指标
主要结局
globe salvage
时间窗: 2-5 years
globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma
次要结局
未报告次要终点
研究者
Bilge Batu Oto
Ophthalmology Specialist, Medical Doctor
Istanbul University - Cerrahpasa (IUC)